Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.
August 26, 2024 17:05 ET
|
Agile Therapeutics, Inc.
Agile Therapeutics has combined with Insud Pharma’s US Subsidiary, Exeltis USA, Inc., expanding an already significant women’s health/contraceptive portfolio Agile Therapeutics Common Shareholders to...
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
June 26, 2024 07:45 ET
|
Agile Therapeutics, Inc.
Agile Therapeutics will combine with Insud Pharma’s US Subsidiary, Exeltis, expanding an already significant Women’s Health/contraceptive portfolio Agile Therapeutics Common Shareholders expected to...
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 15, 2024 16:10 ET
|
Agile Therapeutics, Inc.
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15,...
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
March 28, 2024 08:05 ET
|
Agile Therapeutics, Inc.
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility...
Agile Therapeutics Announces Delisting from Nasdaq
March 25, 2024 16:30 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced that the Company...
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
March 21, 2024 06:35 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial...
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
March 20, 2024 08:15 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial...
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
March 13, 2024 07:31 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare company, today announced that it has paid-off the...
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
February 22, 2024 09:01 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced the entry into a...
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update
February 15, 2024 16:30 ET
|
Agile Therapeutics, Inc.
Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement Until March 25, 2024 Net Revenue for Full Year 2023 Expected to be...